Incipient non-arteritic anterior ischaemic optic neuropathy: a distinct clinical entity, the Singapore scene 3

Share this Article

Singapore Med J 2014; 55(9): 473-475; http://dx.doi.org/10.11622/smedj.2014116
Incipient non-arteritic anterior ischaemic optic neuropathy: a distinct clinical entity, the Singapore scene 3

Chua D, Cullen JF
Correspondence: Dr James F Cullen, jbarrycullen@yahoo.com

ABSTRACT
We report five cases of non-arteritic anterior ischaemic optic neuropathy (NA-AION) where spontaneous resolution of the optic disc swelling occurred, and all relevant visual modalities were normal at presentation and remained so until resolution of the process after a median time of 9.6 weeks. This condition, which can be termed ‘incipient NA?AION’ or ‘threatened NA-AION’, should be recognised so that unnecessary investigations for other and more serious causes of optic disc swelling can be prevented.

Keywords: anterior ischaemic optic neuropathy, spontaneous resolution, visual acuity, visual fields
Singapore Med J 2014; 55(9): 473-475; http://dx.doi.org/10.11622/smedj.2014116

REFERENCES

1. Cullen JF, Por YM. Ischaemic optic neuropathy: the Singapore scene. Singapore Med J 2007; 48:281-6.
PMid:17384872
 
2. Cullen JF, Chung SH. Non-arteritic anterior ischaemic optic neuropathy (NA-AION): outcome for visual acuity and visual field defects, the Singapore scene 2. Singapore Med J 2012; 53:88-90
PMid:22337180
 
3. Hayreh SS, Zimmerman MB. Incipient nonarteritic anterior ischemic optic neuropathy. Ophthalmology 2007; 114:1763-72.
http://dx.doi.org/10.1016/j.ophtha.2006.11.035
 
4. Arnold AC. Ischemic optic neuropathy. In: Miller NR, Newman NJ, eds. Walsh & Hoyt's Clinical Neuro-Ophthalmology. 6th ed. Philadelphia Lippincott Williams & Wilkins, 2005: 377-9.
PMid:15680715
 
5. Hayreh SS. Ischemic optic neuropathies. Heidelberg: Springer, 2011: 265?308.
http://dx.doi.org/10.1007/978-3-642-11852-4_14

Syndecan-1 is a potential biomarker for triple-positive breast carcinomas in Asian women with correlation to survival

Share this Article

Singapore Med J 2014; 55(9): 468-472; http://dx.doi.org/10.11622/smedj.2014115
Syndecan-1 is a potential biomarker for triple-positive breast carcinomas in Asian women with correlation to survival

Lim GH, Tan PH, Jara-Lazaro AR, Thike AA, Sim WC, Yap VB, Yip GW
Correspondence: Dr Lim Geok-Hoon, ghlimsg@yahoo.com.sg

ABSTRACT
INTRODUCTION While overexpression of syndecan-1 has been associated with aggressive breast cancer in the Caucasian population, the expression pattern of syndecan-1 in Asian women remains unclear. Triple-positive breast carcinoma, in particular, is a unique subtype that has not been extensively studied. We aimed to evaluate the role of syndecan-1 as a potential biomarker and prognostic factor for triple-positive breast carcinoma in Asian women.
METHODS Using immunohistochemistry, staining scores of 61 triple?positive breast carcinoma specimens were correlated with patients’ clinicopathological variables such as age, ethnicity, tumour size, histological grade, lymph node status, lymphovascular invasion, associated ductal carcinoma in situ grade, recurrence and overall survival.
RESULTS Syndecan-1 had intense staining scores in triple?positive invasive ductal breast carcinomas when compared to normal breast tissue. On multivariate analysis, syndecan-1 epithelial total percentage and immunoreactivity score showed statistical correlation with survival (p = 0.02).
CONCLUSION The intense staining scores of syndecan-1 and their correlation with overall survival in patients with triple-positive breast carcinoma suggest that syndecan-1 may have a role as a biological and prognostic marker in patients with this specific subtype of breast cancer.

Keywords: Asian women, biomarker, syndecan-1, triple?positive breast cancer
Singapore Med J 2014; 55(9): 468-472; http://dx.doi.org/10.11622/smedj.2014115

REFERENCES

1. Sim X, Ali RA, Wedren S, et al. Ethnic differences in the time trend of female breast cancer incidence: Singapore, 1968-2002. BMC Cancer 2006; 6:261.
http://dx.doi.org/10.1186/1471-2407-6-261
 
2. Leong SP, Shen ZZ, Liu TJ, et al. Is breast cancer the same disease in Asian and Western countries? World J Surg 2010; 34:2308-24.
http://dx.doi.org/10.1007/s00268-010-0683-1
 
3. Yip CH. Breast cancer in Asia. Methods Mol Biol 2009; 471:51-64.
http://dx.doi.org/10.1007/978-1-59745-416-2_3
 
4. Barbareschi M, Maisonneuve P, Aldovini D, et al. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer 2003; 98:474-83.
http://dx.doi.org/10.1002/cncr.11515
 
5. Lendorf ME, Manon-Jensen T, Krongvist P, Multhaupt HA, Couchman JR. Syndecan-1 and syndecan-4 are independent indicators in breast carcinoma. J Histochem Cytochem 2011; 59:615-29.
http://dx.doi.org/10.1369/0022155411405057
 
6. Tsanou E, Ioachim E, Briasoulis E, et al. Clinicopathological study of the expression of syndecan-1 in invasive breast carcinomas. correlation with extracellular matrix components. J Exp Clin Cancer Res 2004; 23:641-50.
PMid:15743035
 
7. Voduc KD, Cheang MC, Tyldesley S, et al. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 2010; 28:1684-91.
http://dx.doi.org/10.1200/JCO.2009.24.9284
 
8. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295:2492-502.
http://dx.doi.org/10.1001/jama.295.21.2492
 
9. Thike AA, Cheok PY, Jara-Lazaro AR, et al. Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Mod Pathol 2010; 23:123-33.
http://dx.doi.org/10.1038/modpathol.2009.145
 
10. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 2009; 7:4-13.
http://dx.doi.org/10.3121/cmr.2008.825
 
11. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 2010; 134:907-22.
PMid:20524868 PMCid:PMC3073033
 
12. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007; 131:18-43.
PMid:19548375
 
13. Nikolova V, Koo CY, Ibrahim SA, et al. Differential roles for membranebound and soluble syndecan-1 (CD138) in breast cancer progression. Carcinogenesis. 2009; 30:397-407.
http://dx.doi.org/10.1093/carcin/bgp001
 
14. Stanley MJ, Stanley MW, Sanderson RD, Zera R. Syndecan-1 expression is induced in the stroma of infiltrating breast carcinoma. Am J Clin Pathol 1999; 112:377-83.
PMid:10478144
 
15. Leivonen M, Lundin J, Nordling S, von Boguslawski K, Haglund C. Prognostic value of syndecan-1 expression in breast cancer. Oncology 2004; 67:11-8.
http://dx.doi.org/10.1159/000080280
 
16. Lee JA, Kim KI, Bae JW, et al; Korean Breast Cancer Society. Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival. Breast Cancer Res Treat 2010; 123:177-87.
http://dx.doi.org/10.1007/s10549-010-0998-5
 
17. Su Y, Zheng Y, Zheng W, et al. Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study. BMC Cancer 2011; 11:292.
http://dx.doi.org/10.1186/1471-2407-11-292
 
18. Götte M, Kersting C, Radke I, Kiesel L, Wülfing P. An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. Breast Cancer Res 2007; 9:R8.
http://dx.doi.org/10.1186/bcr1641
 
19. Marinho VF, Metze K, Sanches FS, Rocha GF, Gobbi H. Lymph vascular invasion in invasive mammary carcinomas identified by the endothelial lymphatic marker D2-40 is associated with other indicators of poor prognosis. BMC Cancer 2008; 8:64.
http://dx.doi.org/10.1186/1471-2407-8-64
 
20. Maeda T, Alexander CM, Friedl A. Induction of syndecan-1 expression in stromal fibroblasts promotes proliferation of human breast cancer cells. Cancer Res 2004; 64:612-21.
http://dx.doi.org/10.1158/0008-5472.CAN-03-2439
 
21. Yang N, Mosher R, Seo S, Beebe D, Friedl A. Syndecan-1 in breast cancer stroma fibroblasts regulates extracellular matrix fiber organization and carcinoma cell motility. Am J Pathol 2011; 178:325-35.
http://dx.doi.org/10.1016/j.ajpath.2010.11.039
 
22. Maeda T, Desouky J, Friedl A. Syndecan-1 expression by stromal fibroblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis. Oncogene 2006; 25:1408-12.
http://dx.doi.org/10.1038/sj.onc.1209168
 
23. Lofgren L, Sahlin L, Jiang S, et al. Expression of syndecan-1 in paired samples of normal and malignant breast tissue from postmenopausal women. Anticancer Res 2007; 27:3045-50.
PMid:17970043

Clinical characteristics, outcome and early induction deaths in patients with acute promyelocytic leukaemia: a five-year experience at a tertiary care centre

Share this Article

Singapore Med J 2014; 55(8): 443-447; http://dx.doi.org/10.11622/smedj.2014105
Clinical characteristics, outcome and early induction deaths in patients with acute promyelocytic leukaemia: a five-year experience at a tertiary care centre

Karim F, Shaikh U, Adil SN, Khurshid M
Correspondence: Dr Farheen Karim, farheen.mahar@aku.edu

ABSTRACT
INTRODUCTION Acute promyelocytic leukaemia (APL) is a distinct clinical and biological subtype of acute myeloid leukaemia. APL is notorious for causing early death during induction therapy, resulting in induction failure. The aim of our study was to report the clinical characteristics, outcome and early induction deaths with regard to patients with APL seen at our hospital.
METHODS This was a retrospective study carried out at Aga Khan University Hospital, Karachi, Pakistan. Patients aged > 15 years diagnosed with APL within the period September 2007–September 2012 were included in the study.
RESULTS Within the study period, 26 patients were diagnosed with APL based on morphology and the detection of t(15;17)(q24.1;q21.1) and promyelocytic leukaemia-retinoic acid receptor alpha (PML-RARA). The male to female ratio was 1:1. The median age of the patients was 41 (range 16–72) years. In all, there were 13 (50.0%) high-risk patients, and early induction death rate was 61.5%. Causes of early induction deaths (n = 16) included haemorrhage in 7 (43.8%) patients, differentiation (ATRA) syndrome in 7 (43.8%) and infection in 2 (12.5%). The survival rate among patients who survived the early period was 70% at 42 months. The relapse rate was 30%.
CONCLUSION Early induction death rate was very high in patients with APL. The most common cause of early induction death in our study was haemorrhage. Outcome among patients with APL was found to be better among those who survived the initial period.

Keywords: adults, death, early, leukaemia, promyelocytic
Singapore Med J 2014; 55(8): 443-447; http://dx.doi.org/10.11622/smedj.2014105

REFERENCES

1. Walter RB, Othus M, Burnett AK, et al. Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. Blood 2003; 121:2424-31.
http://dx.doi.org/10.1182/blood-2012-10-462440
 
2. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985 Oct; 103:620-5.
http://dx.doi.org/10.7326/0003-4819-103-4-620
 
3. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: IARC Press, 2008.
 
4. Stanley M, McKenna RW, Ellinger G, Brunning RD. Classification of 358 Cases of Acute Myeloid Leukemia by FAB Criteria: Analysis of Clinical and Morphologic Features. In: Bloomfield CD, ed. Chronic and Acute Leukemias in Adults. Boston: Martinus Nijhoff Publishers, 1985: 147–74.
http://dx.doi.org/10.1007/978-1-4613-2581-9_5
 
5. Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009; 113:1875-91.
http://dx.doi.org/10.1182/blood-2008-04-150250
 
6. Candoni A, Damiani D, Michelutti A, et al. Clinical characteristics, prognostic factors and multidrug-resistance related protein expression in 36 adult patients with acute promyelocytic leukemia. Eur J Haematol 2003; 71:1-8.
http://dx.doi.org/10.1034/j.1600-0609.2003.00084.x
 
7. Golomb HM, Rowley JD, Vardiman JW, Testa HR, Butler A. "Microgranular" acute promyelocytic leukemia: a distinct clinical, ultrastructural, and cytogenetic entity. Blood 1980; 55:253-9.
PMid:6928105
 
8. Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72:567-72.
PMid:3165295
 
9. Zhang L, Zhu X. Epidemiology, diagnosis and treatment of acute promyelocytic leukemia in children: the experience in China. Mediterr J Hematol Infect Dis 2012; 4:e2012012.
http://dx.doi.org/10.4084/mjhid.2012.012
 
10. Tallman MS, Nabhan C. Management of acute promyelocytic leukemia. Curr Oncol Rep 2002; 4:381-9.
http://dx.doi.org/10.1007/s11912-002-0031-1
 
11. Douer D. Advances in the treatment of relapsed acute promyelocytic leukemia. Acta Haematol 2002; 107:1-17.
http://dx.doi.org/10.1159/000046623
 
12. Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002; 99:759-67.
http://dx.doi.org/10.1182/blood.V99.3.759
 
13. Sanz MA, Martín G, Lo Coco F. Choice of chemotherapy in induction, consolidation and maintenance in acute promyelocytic leukemia. Best Pract Res Clin Haematol 2003; 16:433-51.
http://dx.doi.org/10.1016/S1521-6926(03)00040-9
 
14. Tallman MS, Altman JK. How I treat acute promyelocytic leukemia. Blood 2009; 114:5126-35.
http://dx.doi.org/10.1182/blood-2009-07-216457
 
15. Di Bona E, Avvisati G, Castaman G, et al. Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukemia. Br J Haematol 2000; 108:689-95.
http://dx.doi.org/10.1046/j.1365-2141.2000.01936.x
 
16. Hillestad LK. Acute promyelocytic leukemia. Acta Med Scand 1957; 159:189-94.
http://dx.doi.org/10.1111/j.0954-6820.1957.tb00124.x
 
17. Rovelli A, Biondi A, Cantù Rajnoldi A, et al. Microgranular variant of acute promyelocytic leukemia in children. J Clin Oncol 1992; 10:1413-8.
PMid:1517784
 
18. Tallman MS, Brenner B, Serna Jde L, et al. Meeting report. Acute promyelocytic leukemia-associated coagulopathy, 21 January 2004, London, United Kingdom. Leuk Res 2005; 29:347-51.
http://dx.doi.org/10.1016/j.leukres.2004.04.021
 
19. de la Serna J, Montesinos P, Vellenga E, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 2008; 111:3395-402.
http://dx.doi.org/10.1182/blood-2007-07-100669
 
20. Serefhanoglu S, Buyukasik Y, Goker H, et al. Clinical features and outcomes of 49 Turkish patients with acute promyelocytic leukemia who received ATRA and anthracyclines (PETHEMA protocol) therapy. Leuk Res 2010; 34:e317-9.
http://dx.doi.org/10.1016/j.leukres.2010.07.027
 
21. Sanz MA, Martín G, González M, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study of the PETHEMA group. Blood 2004; 103:1237-43.
http://dx.doi.org/10.1182/blood-2003-07-2462
 
22. Lehmann S, Ravn A, Carlsson L, et al. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia 2011; 25:1128-34.
http://dx.doi.org/10.1038/leu.2011.78
 
23. Park JH, Qiao B, Panageas KS, Schymura MJ, Jurcic JG, Rosenblat TL, et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood 2011: 118:1248-54.
http://dx.doi.org/10.1182/blood-2011-04-346437
 
24. Esteve J, Escoda L, Martín G, et al. Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention. Leukemia 2007; 21:446-52.
http://dx.doi.org/10.1038/sj.leu.2404501
 
25. Avvisati G, Lo Coco F, Diverio D, et al. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood 1996; 88:1390-8.
PMid:8695858
 
26. Avvisati G, Lo-Coco F, Paoloni FP, et al. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood 2011; 117:4716-25.
http://dx.doi.org/10.1182/blood-2010-08-302950
 
27. Montesinos P, Bergua JM, Vellenga E, et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood 2009; 113:775-83.
http://dx.doi.org/10.1182/blood-2008-07-168617
 
28. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008; 111:2505-15.
http://dx.doi.org/10.1182/blood-2007-07-102798
 
29. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 2002; 100:4298-302.
http://dx.doi.org/10.1182/blood-2002-02-0632
 
30. Jacomo RH, Melo RA, Souto RF, et al. Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines. Haematologica 2007; 92:1431-2.
http://dx.doi.org/10.3324/haematol.10874
 
31. Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 1997; 90:1014-21.
PMid:9242531
 
32. Kanamaru A, Takemoto Y, Tanimoto M, et al. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group. Blood 1995; 85:1202-6.
PMid:7858250
 
33. Raza S, Ullah K, Ahmed P, Khan B. Comparison of anthracycline-based combination chemotherapy with or without all-trans retinoic acid in acute promyelocytic leukemia. J Coll Physicians Surg Pak 2008; 18:546-50.
PMid:18803891
 
34. Pagoni M, Garofalaki M, Panitsas F, et al. Acute promyelocytic leukemia: an experience on 95 greek patients treated in the all-trans-retinoic Acid era. Mediterr J Hematol Infect Dis 2011; 3:e2011053.
http://dx.doi.org/10.4084/mjhid.2011.053
 
35. Mitrovic M, Suvajdzic N, Bogdanovic A, et al. International Society of Thrombosis and Hemostasis Scoring System for disseminated intravascular coagulation ≥ 6: a new predictor of hemorrhagic early death in acute promyelocytic leukemia. Med Oncol 2013; 30:478.
http://dx.doi.org/10.1007/s12032-013-0478-y
 
36. Sanz MA, Montesinos P, Rayón C, et al. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood 2010; 115:5137-46.
http://dx.doi.org/10.1182/blood-2010-01-266007
 
37. Au WY, Fung A, Chim CS, et al. FLT-3 aberrations in acute promyelocytic leukaemia: clinicopathological associations and prognostic impact. Br J Haematol 2004; 125:463-9.
http://dx.doi.org/10.1111/j.1365-2141.2004.04935.x

Attitudes and perceptions of the general Malaysian public regarding family presence during resuscitation

Share this Article

Singapore Med J 2014; 55(8): 439-442; http://dx.doi.org/10.11622/smedj.2014104
Attitudes and perceptions of the general Malaysian public regarding family presence during resuscitation

Chew KS, Ghani ZA
Correspondence: Dr Chew Keng Sheng, cksheng74@yahoo.com

ABSTRACT
INTRODUCTION
Family presence (FP) during resuscitation is an increasingly favoured trend, as it affords many benefits to the critically ill patient’s family members. However, a previously conducted study showed that only 15.8% of surveyed Malaysian healthcare staff supported FP during resuscitation.
METHODS This cross-sectional study used a bilingual self-administered questionnaire to examine the attitudes and perceptions of the general Malaysian public toward the presence of family members during resuscitation of their loved ones. The questionnaires were randomly distributed to Malaysians in three different states and in the federal territory of Kuala Lumpur.
RESULTS Out of a total of 190 survey forms distributed, 184 responses were included for analysis. Of the 184 respondents, 140 (76.1%) indicated that they favoured FP during resuscitation. The most common reason cited was that FP during resuscitation provides family members with the assurance that everything possible had been done for their loved ones (n = 157, 85.3%). Respondents who had terminal illnesses were more likely to favour FP during resuscitation than those who did not, and this was statistically significant (95.0% vs. 73.8%; p = 0.04).
CONCLUSION FP during resuscitation was favoured by a higher percentage of the general Malaysian public as compared to Malaysian healthcare staff. This could be due to differences in concerns regarding the resuscitation process between members of the public and healthcare staff.

Keywords: family presence, invasive procedures, Malaysian, resuscitation
Singapore Med J 2014; 55(8): 439-442; http://dx.doi.org/10.11622/smedj.2014104

REFERENCES

1. Baumhover N, Hughes L. Spirituality and support for family presence during invasive procedures and resuscitations in adults. Am J Crit Care 2009; 18:357-66.
http://dx.doi.org/10.4037/ajcc2009759
 
2. Mazer MA, Cox LA, Capon JA. The public's attitude and perception concerning witnessed cardiopulmonary resuscitation. Crit Care Med 2006; 34:2925-8.
PMid:17075365
 
3. MacLean SL, Guzzetta CE, White C, et al. Family presence during cardiopulmonary resuscitation and invasive procedures: practices of critical care and emergency nurses. Am J Crit Care 2003; 12:246-57.
PMid:12751400
 
4. Ersoy G, Yanturali S, Suner S, et al. Turkish patient relatives' attitudes towards family-witnessed resuscitation and affecting sociodemographic factors. Eur J Emerg Med 2009; 16:188-93.
http://dx.doi.org/10.1097/MEJ.0b013e328311a8dc
 
5. Meyers TA, Eichhorn DJ, Guzzetta CE, et al. Family presence during invasive procedures and resuscitation. Am J Nurs 2000; 100:32-42.
PMid:10683641
 
6. Sheng CK, Lim CK, Rashidi A. A multi-center study on the attitudes of Malaysian emergency health care staff towards allowing family presence during resuscitation of adult patients. Int J Emerg Med 2010; 3:287-91.
PMid:21373294 PMCid:PMC3047822
 
7. Emergency Nurses Association (ENA). Position statement - Family presence during invasive procedures and resuscitation in the emergency department [online]. Available at: http://www.ena.org/SiteCollectionDocuments/Position%20Statements/FamilyP.... Accessed June 2, 2013.
 
8. Ong ME, Chung WL, Mei JS. Comparing attitudes of the public and medical staff towards witnessed resuscitation in an Asian population. Resuscitation 2007; 73:103-8.
http://dx.doi.org/10.1016/j.resuscitation.2006.08.007
 
9. Timmermans S. High touch in high tech: the presence of relatives and friends during resuscitative efforts. Sch Inq Nurs Pract 1997; 11:153-68.
PMid:9329276

Femoral head diameter in the Malaysian population

Share this Article

Singapore Med J 2014; 55(8): 436-438; http://dx.doi.org/10.11622/smedj.2014103
Femoral head diameter in the Malaysian population

Lee CK, Kwan MK, Merican AM, Ng WM, Saw LB, Teh KK, Krishnan M, Ramiah R
Correspondence: Dr Lee Chee Kean, kenetto@hotmail.com

ABSTRACT
INTRODUCTION Hip arthroplasty is commonly performed worldwide. The objective of this study was to determine the diameter of the femoral head in the Malaysian population in relation to gender and race (i.e. among Malay, Chinese and Indian patients).
METHODS This was a retrospective cross-sectional study performed between January 1995 and December 2006, evaluating the femoral head diameters of all patients aged 50 years and above who underwent hemiarthroplasty at two major hospitals in Malaysia.
RESULTS A total of 945 femoral heads (663 women, 282 men) were evaluated. The mean age of the patients in our cohort was 75.2 ± 9.4 (range 50–101) years. The mean femoral head diameter (with intact articular cartilage) was 44.9 ± 3.2 (range 38–54) mm. In our study, men had a significantly larger mean femoral head diameter than women (47.7 ± 2.8 mm vs. 43.7 ± 2.4 mm; p < 0.05). Patients of Chinese ethnicity were also found to have significantly larger femoral head diameters, when compared among the three races studied (p < 0.05).
CONCLUSION Malaysians have a mean femoral head diameter of 44.9 ± 3.2 mm. Among our patients, Chinese patients had a significantly larger femoral head size than Malay and Indian patients. We also found that, in our cohort, men had significantly larger femoral head diameters than women.

Keywords: Chinese, femoral head diameter, Indian, Malay, Malaysia
Singapore Med J 2014; 55(8): 436-438; http://dx.doi.org/10.11622/smedj.2014103

REFERENCES

1. National Joint Registry. National Joint Registry for England, Wales and Northern Ireland – 10th Annual Report 2013. In: National Joint Registry – Annual Reports [online]. Available at: http://www.njrcentre.org.uk/njrcentre/Portals/0/Documents/England/Report.... Accessed July 10, 2014.
 
2. American Joint Replacement Registry. American Joint Replacement Registry Fall 2013 Update. In: AJRR Home [online]. Available at: http://teamwork.aaos.org/ajrr/AJRR%20Documents/AJRR%20Fall%202013_F11062.... Accessed July 10, 2014.
 
3. Harkess JW. Arthroplasty of hip. In: Canale ST, Beatty JH, eds. Campbell's operative orthopaedics. 10th ed. Philadelphia: Mosby Elsevier, 2007: 348?371.
 
4. Noble PC, Alexander JW, Lindahl LJ, et al. The anatomic basis of femoral componnet design. Clin Orthop Relat Res 1988; 235:148-65.
PMid:3416522
 
5. Hoaglund FT, Low WD. Anatomy of the femoral neck and head, with comparative data from Caucasians and Hong Kong Chinese. Clin Orthop Relat Res 1980; 152:10-6.
PMid:7438592
 
6. Massin P, Geais L, Astoin E, Simondi M, Lavaste F. The anatomic basis for the concept of lateralized femoral stems: a frontal plane radiographic study of the proximal femur. J Arthroplasty 2000; 15:93-101.
http://dx.doi.org/10.1016/S0883-5403(00)91337-8
 
7. Chauhan R, Paul S, Dhaon BK. Anatomical parameters of North Indian hip joints: cadaveric study. J Anat Soc India 2002; 51:39-42.
 
8. Department of Statistics Malaysia. Census of Population and Housing Malaysia 2000 [online]. Available at: http://www.statistics.gov.my/eng/index.php. Accessed September 5, 2008.
 
9. Department of Statistics Malaysia. Population (Updated 5 September 2008) [online]. Available at: http://www.statistics.gov.my/eng/index.php. Accessed September 5, 2008.
 
10. Maggi S, Kelsey JL, Litvak J, Keyse SP. Incidence of hip fractures in the elderly: a cross-national analysis. Osteoporos Int 1991; 1:232-41.
http://dx.doi.org/10.1007/BF03187467
 
11. Zhang YY, Liu PY, Lu Y, et al. Race and sex differences and contribution of height: a study on bone size in healthy Caucasians and Chinese. Am J Hum Biol 2005; 17:568-75.
http://dx.doi.org/10.1002/ajhb.20427
 
12. Wyler A, Bousson V, Bergot C, et al. Hyaline cartilage thickness in radiographically normal cadaveric hips: comparison of spiral CT arthrographic and macroscopic measurements. Radiology 2007; 242:441?9.
http://dx.doi.org/10.1148/radiol.2422051393
 
13. Smith & Nephew. Birmingham Hip Resurfacing System [online]. Available at: http://www.smith-nephew.com/documents/nl-bhr-surgicaltechnique.pdf. Accessed July 10, 2014.

Association between the use of gel pads under patients' knees and the incidence of peroneal neuropathy following liver transplantation

Share this Article

Singapore Med J 2014; 55(8): 432-435; http://dx.doi.org/10.11622/smedj.2014102
Association between the use of gel pads under patients' knees and the incidence of peroneal neuropathy following liver transplantation

Kim GS, Yoon JS, Kee R, Shin YH, Ko JS, Gwak MS, Hwang JH, Lee SK
Correspondence: Dr Jin Sun Yoon, medisun74@naver.com

ABSTRACT
INTRODUCTION There have been intermittent reports of peroneal neuropathy (PN) occurring after liver transplantation. Although PN may not be viewed as a serious complication by liver transplant (LT) recipients who require the transplant for survival, PN can significantly reduce quality of life. The incidence of PN appears to have increased after the use of gel pads was introduced. These gel pads, which are placed under patients’ knees during surgery, are used to reduce lower back strain and prevent contact between the peroneal nerve at the fibular head and the hard surface of the operating table. The aim of the present study was to investigate the association, if any, between the use of gel pads and the incidence of PN.
METHODS The medical records of 261 adult LT recipients were retrospectively reviewed. The recipients were divided into gel pad (n = 167) and non-gel pad (n = 94) groups. The incidence and possible risk factors of PN were compared between the two groups.
RESULTS The overall incidence of PN was 8.0% (21/261). The occurrence of PN was significantly higher in the gel pad group than in the non-gel pad group (10.8% vs. 3.2%; p < 0.05). Other possible risk factors were comparable between the two patient groups.
CONCLUSION As the use of gel pads may increase the incidence of PN, we recommend against the use of gel pads under the knees of LT recipients.

Keywords: liver transplantation, patient positioning, peroneal neuropathy
Singapore Med J 2014; 55(8): 432-435; http://dx.doi.org/10.11622/smedj.2014102

REFERENCES

1. Yoon JS, Gwak MS, Yang M, et al. Peroneal neuropathy after liver transplantation. Transplant Proc 2008; 40:2552-3.
http://dx.doi.org/10.1016/j.transproceed.2008.07.036
 
2. Moreno E, Gómez SR, Gonzalez I, et al. Neurologic complications in liver transplantation. Acta Neurol Scand 1993; 87:25-31.
http://dx.doi.org/10.1111/j.1600-0404.1993.tb04070.x
 
3. Nonthasoot B, Sirichindakul B, Nivatvongs S, Sangsubhan C. Common peroneal nerve palsy: an unexpected complication of liver surgery. Transplant Proc 2006; 38:1396-7.
http://dx.doi.org/10.1016/j.transproceed.2006.02.104
 
4. Atalay A, Karatas M, Turhan N, et al. Bilateral drop-foot after orthotopic liver transplant. Transplant Proc 2006; 38:1471-3.
http://dx.doi.org/10.1016/j.transproceed.2006.02.130
 
5. Singhal A, Varma M, Goyal N, et al. Peroneal neuropathy following liver transplantation: possible predisposing factors and outcome. Exp Clin Transplant 2009; 7:252-5.
PMid:20353377
 
6. Sawyer RJ, Richmond MN, Hickey JD, Jarrratt JA. Peripheral nerve injuries associated with anaesthesia. Anaesthesia 2000; 55:980-91.
http://dx.doi.org/10.1046/j.1365-2044.2000.01614.x
 
7. Borgeat A, Ekatodramis G. Nerve injury associated with regional anesthesia. Curr Top Med Chem 2001; 1:199-203.
http://dx.doi.org/10.2174/1568026013395272
 
8. Britt BA, Gordon RA. Peripheral nerve injuries associated with anaesthesia. Can Anaesth Soc J 1964; 11:514-36.
http://dx.doi.org/10.1007/BF03005094
 
9. Cheney FW, Domino KB, Caplan RA, Posner KL. Nerve injury associated with anesthesia: a closed claims analysis. Anesthesiology 1999; 90:1062-9.
http://dx.doi.org/10.1097/00000542-199904000-00020
 
10. Kroll DA, Caplan RA, Posner K, Ward RJ, Cheney FW. Nerve injury associated with anesthesia. Anesthesiology 1990; 73:202-7.
http://dx.doi.org/10.1097/00000542-199008000-00002
 
11. Sirinan C, Akavipat P, Srisawasdi S, Tanudsintum S, Weerawatganon T. The Thai Anesthesia Incidents Study (THAI Study) on nerve injury associated with anesthesia. J Med Assoc Thai 2005; 8888 Suppl 7:S102-5.
 
12. Warner MA, Martin JT, Schroeder DR, Offord KP, Chute CG. Lower-extremity motor neuropathy associated with surgery performed on patients in a lithotomy position. Anesthesiology 1994; 81:6-12.
http://dx.doi.org/10.1097/00000542-199407000-00004
 
13. Warner MA, Warner DO, Harper CM, Schroeder DR, Maxson PM. Lower extremity neuropathies associated with lithotomy positions. Anesthesiology 2000; 93:938-42.
http://dx.doi.org/10.1097/00000542-200010000-00010
 
14. McEwen DR. Intraoperative positioning of surgical patients. AORN J 1996; 63:1059-63.
http://dx.doi.org/10.1016/S0001-2092(06)63293-6
 
15. Recommended practices for positioning the patient in the perioperative setting. In: Conner R, Blanchard JC, Reno D, AORN, eds. Perioperative Standards and Recommended Practices. Denver: AORN, 2009: 525-48.
 
16. ERCI. Pressure ulcers. Healthcare Risk ControlHRC Risk Analysis. 2006; 3(Nursing 4):1-37.
 
17. Walton-Geer PS. Prevention of pressure ulcers in the surgical patient. AORN J 2009; 89:538-48.
http://dx.doi.org/10.1016/j.aorn.2008.12.022
 
18. Parks BJ. Postoperative peripheral neuropathies. Surgery 1973; 74:348-57.
PMid:4722702
 
19. Dawson DM, Krarup C. Perioperative nerve lesions. Arch Neurol 1989; 46:1355-60.
http://dx.doi.org/10.1001/archneur.1989.00520480099027
 
20. Romfh JH, Currier RD. Sciatic neuropathy induced by the lithotomy position. Arch Neurol 1983; 40:127.
http://dx.doi.org/10.1001/archneur.1983.04050020089025
 
21. Winfree CJ, Kline DG. Intraoperative positioning nerve injuries. Surg Neurol 2005; 63:5-18.
http://dx.doi.org/10.1016/j.surneu.2004.03.024

Granulomatous cervicofacial lymphadenitis in children: a nine-year study in Singapore

Share this Article

Singapore Med J 2014; 55(8): 427-431; http://dx.doi.org/10.11622/smedj.2014101
Granulomatous cervicofacial lymphadenitis in children: a nine-year study in Singapore

Thoon KC, Subramania K, Chong CY, Chang KT, Tee NW
Correspondence: Dr Koh Cheng Thoon, Thoon.Koh.Cheng@kkh.com.sg

ABSTRACT
INTRODUCTION Granulomatous cervicofacial lymphadenitis (GCL) is not uncommon in children. Nontuberculous mycobacteria (NTM) seem to be the predominant cause. We sought to study the clinical and microbiological profile of patients with GCL, and identify features that may impact outcome.
METHODS Children aged < 16 years who presented to KK Women’s and Children’s Hospital, Singapore, between January 1998 and December 2006, and who had GCL were identified from laboratory records. Clinical and laboratory data was collected and analysed for risk factors for patients with positive lymph node cultures, and for patients with and without recurrence after treatment.
RESULTS In all, 60 children were identified, with a median age of 56 (interquartile range [IQR] 34–101) months. Median duration of symptoms before presentation was 5 (IQR 4–8) weeks. The majority presented with single (73.3%) or unilateral (96.7%) lymphadenopathy, located in the submandibular, preauricular/parotid or infra-/post-auricular region (76.7%). Out of 51 patients, 26 (51.0%) had a tuberculin skin test reading of ≥ 10 mm. Out of 52 patients, 10 (19.2%) had positive mycobacterial cultures, which included seven isolates of NTM. Out of 34 cases, tuberculous polymerase chain reaction was positive in 11 (32.4%). With regard to recurrence after initial treatment, age < 5 years at presentation was found to be a predictor for recurrence (p = 0.008), while initial complete excision of affected nodes predicted no recurrence (p = 0.003).
CONCLUSION In our study, younger age was noted to be associated with a higher chance of recurrence, while complete excision of the involved node at initial presentation predicted non-recurrence.

Keywords: cervicofacial lymphadenitis, granulomatous, nontuberculous mycobacteria, Singapore
Singapore Med J 2014; 55(8): 427-431; http://dx.doi.org/10.11622/smedj.2014101

REFERENCES

1. Gosche JR, Vick L. Acute, subacute, and chronic cervical lymphadenitis in children. Semin Pediatr Surg 2006; 15:99-106.
http://dx.doi.org/10.1053/j.sempedsurg.2006.02.007
 
2. Chesney PJ. Cervical Lymphadenitis and Neck Infections. In: Long SS, Pickering LK, Prober CG, eds. Principles and Practice of Pediatric Infectious Diseases, 2nd ed. Philadelphia, PA: Churchill Livingstone, 2003: 165-76.
 
3. Moussatos GH, Baffles TG. Cervical masses in infants and children. Pediatrics 1963; 32:251-6.
PMid:14044453
 
4. Lake AM, Oski FA. Peripheral lymphadenopathy in childhood. Ten-year experience with excisional biopsy. Am J Dis Child 1978; 132:357-9.
http://dx.doi.org/10.1001/archpedi.1978.02120290029003
 
5. Benjamin DR. Granulomatous lymphadenitis in children. Arch Pathol Lab Med 1987; 111:750-3.
PMid:3632289
 
6. Knight PJ, Mulne AF, Vassy LE. When is lymph node biopsy indicated in children with enlarged peripheral nodes? Pediatrics 1982; 69:391-6.
PMid:7070884
 
7. Lai KK, Stottmeier KD, Sherman IH, McCabe WR. Mycobacterial cervical lymphadenopathy. Relation of etiologic agents to age. JAMA 1984; 251:1286?8.
http://dx.doi.org/10.1001/jama.1984.03340340026019
 
8. Robson CD. Imaging of granulomatous lesions of the neck in children. Radiol Clin North Am 2000; 38:969-77.
http://dx.doi.org/10.1016/S0033-8389(05)70215-3
 
9. Albright JT, Pransky SM. Nontuberculous mycobacterial infections of the head and neck. Pediatr Clin North Am 2003; 50:503-14.
http://dx.doi.org/10.1016/S0031-3955(03)00024-5
 
10. Wolinsky E. Mycobacterial lymphadenitis in children: a prospective study of 105 children nontuberculous cases with long-term follow-up. Clin Infect Dis 1995; 20:954-63.
http://dx.doi.org/10.1093/clinids/20.4.954
 
11. Wallace RJ Jr, Cook JL, Glassroth J, et al. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association. Am J Respir and Crit Care Med 1997; 156:S1-S25.
 
12. Henriques B, Hoffner SE, Petrini B, et al. Infection with Mycobacterium malmoense in Sweden: a report of 221 cases. Clin Infect Dis 1994; 18:596?600.
http://dx.doi.org/10.1093/clinids/18.4.596
 
13. Thavagnanam S, McLoughlin LM, Hill C, Jackson PT. Atypical mycobacterial infections in children: the case for early diagnosis. Ulster Med J 2006; 75:192-4.
PMid:16964810 PMCid:PMC1891767
 
14. Grange JM, Yates MD, Pozniak A. Bacteriologically confirmed non-tuberculous mycobacterial lymphadenitis in south east England: a recent increase in the number of cases. Arch Dis Child 1995; 72:516-7.
http://dx.doi.org/10.1136/adc.72.6.516
 
15. Jindal N, Devi B, Aggarwal A. Mycobacterial cervical lymphadenitis in childhood. Indian J Med Sci 2003; 57:1-15.
 
16. Huebner RE, Schein MF, Cauthen GM, Geiter LJ, O'Brien RJ. Usefulness of skin testing with mycobacterial antigens in children with cervical lymphadenopathy. Pediatr Infect Dis J 1992; 11:450-6.
http://dx.doi.org/10.1097/00006454-199206000-00006
 
17. Starke JR. Management of nontuberculous mycobacterial cervical adenitis. Pediatric Infect Dis J 2000; 7:674-5.
http://dx.doi.org/10.1097/00006454-200007000-00028
 
18. Starke JR. Interferon-gamma release assays for diagnosis of tuberculosis infection in children. Pediatr Infect Dis J 2006; 25:941-2.
http://dx.doi.org/10.1097/01.inf.0000239685.49999.d3
 
19. Hazra R, Robson CD, Perez-Atayde AR, Husson RN. Lymphadenitis due to nontuberculous mycobacteria in children: presentation and response to therapy. Clin Infect Dis 1999; 28:123-9.
http://dx.doi.org/10.1086/515091
 
20. White MP, Bangash H, Goel KM, Jenkins PA. Non-tuberculous mycobacterial lymphadenitis. Arch Dis Child 1986; 61:368-71.
http://dx.doi.org/10.1136/adc.61.4.368
 
21. Fergusson JA, Simpson E. Surgical treatment of atypical mycobacterial cervicofacial adenitis in children. Aust NZ J Surg 1999; 69:426-9.
http://dx.doi.org/10.1046/j.1440-1622.1999.01593.x
 
22. Makhani S, Postlethwaite KR, Renny NM, Kerawala CJ, Carton AT. Atypical cervico-facial mycobacterial infections in childhood. Br J Oral Max Surg 1998; 36:119-22.
http://dx.doi.org/10.1016/S0266-4356(98)90179-6
 
23. Lindeboom JA, Kuijper EJ, Bruijnesteijn van Coppenraet ES, Lindeboom R, Prins JM. Surgical excision versus antibiotic treatment for nontuberculous mycobacterial cervicofacial lymphadenitis in children: a multicenter, randomized controlled trial. Clin Infect Dis 2007; 44:1057-64.
http://dx.doi.org/10.1086/512675
 
24. Zeharia A, Eidlitz-Markus T, Haimi-Cohen Y, et al. Management of nontuberculous mycobacteria-induced cervical lymphadenitis with observation alone. Pediatr Infect Dis J 2008; 27:920-2.
http://dx.doi.org/10.1097/INF.0b013e3181734fa3
 
25. Starke JR. Commentary: The natural history of nontuberculous mycobacterial cervical adenitis. Pediatr Infect Dis J 2008; 27:923-4.
http://dx.doi.org/10.1097/INF.0b013e318187807c

Cosmetic procedures among youths: a survey of junior college and medical students in Singapore

Share this Article

Singapore Med J 2014; 55(8): 422-426; http://dx.doi.org/10.11622/smedj.2014100
Cosmetic procedures among youths: a survey of junior college and medical students in Singapore

Ng JH, Yeak S, Phoon N, Lo S
Correspondence: Dr Ng Jia Hui, jiahui.ng@mohh.com.sg

ABSTRACT
INTRODUCTION
Although cosmetic procedures have become increasingly popular among the younger population in recent years, limited research on this subject has been done in the Asian context. We aimed to explore the views and knowledge regarding cosmetic procedures among junior college (JC) and medical students in Singapore.
METHODS In the first phase of the study, a cross-sectional, self-administered survey of 1,500 JC students aged 16–21 years from six JCs was conducted in 2010. The same survey was then conducted on a random sample of Year 2–5 medical students from an undergraduate medical school in 2011.
RESULTS In total, 1,164 JC and 241 medical students responded to the surveys. There was an overall female to male ratio of 1.3:1. Of all the respondents, 2.5% of the JC students and 3.0% of the medical students admitted to having undergone cosmetic procedures. Among those who claimed to have never had cosmetic procedures done, 9.0% and 44.0% of the JC and medical students, respectively, responded that they would consider such procedures in the future. Those who disapproved of their peers undergoing cosmetic surgery comprised 35.0% of JC students and 56.8% of medical students. Among the JC and medical students, 52.0% and 36.1%, respectively, were unaware of any risks associated with cosmetic procedures.
CONCLUSION The younger population is increasingly accepting of cosmetic procedures. However, there is a general lack of understanding of the risks associated with such procedures. Education of both the general public and medical students may help prevent potential medicolegal issues.

Keywords: attitudes, cosmetic procedures, students, survey
Singapore Med J 2014; 55(8): 422-426; http://dx.doi.org/10.11622/smedj.2014100

REFERENCES

1. 2011 Plastic Surgery Procedural Statistics. In: American Society for Plastic Surgeons National Clearinghouse of Plastic Surgery Procedural Statistics [online]. Available at: http://www.plasticsurgery.org. Accessed September 18, 2011.
 
2. Simis KJ, Hovius SE, de Beaufort ID, Verhulst FC, Koot HM. After plastic surgery: adolescent-reported appearance ratings and appearance-related burdens in patient and general population groups. Plast Reconstr Surg 2002; 109:9-17.
http://dx.doi.org/10.1097/00006534-200201000-00003
 
3. Crockett RJ, Pruzinsky T, Persing JA. The influence of plastic surgery "Reality TV" on cosmetic surgery patient expectations and decision making. Plast Reconstr Surg 2007; 120:316-24.
http://dx.doi.org/10.1097/01.prs.0000264339.67451.71
 
4. Javo IM, Sørlie T. Psychosocial predictors of an interest in cosmetic surgery among young Norwegian women: a population-based study. Plast Surg Nurs 2010; 30:180-6.
http://dx.doi.org/10.1097/PRS.0b013e3181bcf290
 
5. Steinberg L. Risk-taking in adolescence: What changes, and why? In: New York Academy of Sciences 2003 meeting on adolescent brain development [online]. Available at: http://www.nyas.org/ebriefreps/main.asp?intSubsectionID320#12. Accessed March 21, 2008.
 
6. Pearl A, Weston J. Attitudes of adolescents about cosmetic surgery. Ann Plast Surg 2003; 50:628-30.
http://dx.doi.org/10.1097/01.SAP.0000054365.54173.95
 
7. Sarwer DB. Plastic surgery in children and adolescents. In: Thompson JK, Smolak L, eds. Body Image, Eating Disorders, and Obesity in Youth: Assessment, Prevention, and Treatment. Washington DC: APA, 2000: 341?66.
 
8. Swami V. Translation and validation of the Malay Acceptance of Cosmetic Surgery Scale. Body Image 2010; 7:372-5.
http://dx.doi.org/10.1016/j.bodyim.2010.07.005
 
9. Swami V, Campana AN, Ferreira L, et al. The Acceptance of Cosmetic Surgery Scale: initial examination of its factor structure and correlates among Brazilian adults. Body Image 2011; 8:179-85.
PMid:21354875
 
10. 2010 International Communications Research. In: American Academy of Facial Plastic and Reconstructive Surgery Membership study. [online] Available at: http://www.aafprs.org/media/stats_polls/aafprsMedia2010.pdf. Accessed September 18, 2011.
 
11. Thompson JK, Smolak L. Body Image, Eating Disorders, and Obesity in Youth: Assessment, Prevention, and Treatment. Washington DC: APA; 2000: 166-341.
PMid:10930969 PMCid:PMC2014396

Understanding patients' perspective of statin therapy: can we design a better approach to the management of dyslipidaemia? A literature review

Share this Article

Singapore Med J 2014; 55(8): 416-421; http://dx.doi.org/10.11622/smedj.2014099
Understanding patients' perspective of statin therapy: can we design a better approach to the management of dyslipidaemia? A literature review

Chee YJ, Chan V, Tan NC
Correspondence: Dr Chee Ying Jie, cheeyingjie.chee@mohh.com.sg

ABSTRACT
INTRODUCTION Dyslipidaemia leads to atherosclerosis and is a major risk factor for cardiovascular diseases. In clinical trials, 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, or statins, have been shown to effectively reduce dyslipidaemia. Despite the availability and accessibility of statins, myocardial infarctions and cerebrovascular accidents remain among the top causes of mortality in developed countries, including Singapore. This enigma could be attributed to suboptimal adherence to statin therapy. The present literature review aimed to evaluate patients’ perceptions of statin therapy.
METHODS We searched PubMed and other databases for articles published in English from October 1991 to May 2012 containing keywords such as ‘patient’, ‘views’, ‘perceptions’, ‘adherence’, ‘statin’ and ‘dyslipidaemia’. Of the 122 eligible studies retrieved, 58 were reviewed. The findings were categorised and framed in accordance with the Health Belief Model.
RESULTS Patients with dyslipidaemia appeared to underestimate their susceptibility to dyslipidaemia-related complications, partly due to their demographic profiles. Failure to appreciate the severity of potential complications was a major hindrance toward adherence to statin therapy. Other factors that affected a patient’s adherence included lack of perceived benefits, perceived side effects, the cost of statins, poor physician-patient relationship, and overestimation of the effectiveness of diet control as a treatment modality.
CONCLUSION Existing evidence suggests that the cause of poor adherence to statin therapy is multifactorial. The use of the Health Belief Model to present the results of our literature review provides a systematic framework that could be used to design a patient-centric approach for enhancing adherence to statin therapy.

Keywords: adherence, dyslipidaemia, patient, perceptions, statin
Singapore Med J 2014; 55(8): 416-421; http://dx.doi.org/10.11622/smedj.2014099

REFERENCES

1. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-78.
http://dx.doi.org/10.1016/S0140-6736(05)67394-1
 
2. Cholesterol Treatment Trialists' (CTT) Collaborators, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380:581-90.
http://dx.doi.org/10.1016/S0140-6736(12)60367-5
 
3. Bates TR, Connaughton VM, Watts GF. Non-adherence to statin therapy: a major challenge for preventive cardiology. Expert Opin Pharmacother 2009; 10:2973-85.
http://dx.doi.org/10.1517/14656560903376186
 
4. Ho KT, Chin KW, Ng KS, et al. The A-SACT (Achievement in Singapore of Cholesterol Targets) study in patients with coronary heart disease. Am J Cardiovasc Drugs 2006; 6:383-91.
http://dx.doi.org/10.2165/00129784-200606060-00005
 
5. Ansell BJ. Not getting to goal: the clinical costs of noncompliance. J Manag Care Pharm 2008; 14:9-15.
PMid:18693783
 
6. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005; 43:521-30.
http://dx.doi.org/10.1097/01.mlr.0000163641.86870.af
 
7. Chaudhry HJ, McDermott B. Recognizing and improving patient nonadherence to statin therapy. Curr Atheroscler Rep 2008; 10:19-24.
http://dx.doi.org/10.1007/s11883-008-0004-4
 
8. Ford I, Murray H, Packard CJ, et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007; 357:1477-86.
http://dx.doi.org/10.1056/NEJMoa065994
 
9. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002; 288:455-61.
http://dx.doi.org/10.1001/jama.288.4.455
 
10. Rosenstock IM, Strecher VJ, Becker MH. Social learning theory and the Health Belief Model. Health Educ Q 1988; 15:175-83.
http://dx.doi.org/10.1177/109019818801500203
 
11. Wong MC, Jiang JY, Griffiths SM. Adherence to lipid-lowering agents among 11,042 patients in clinical practice. Int J Clin Pract 2011; 65:741-8.
http://dx.doi.org/10.1111/j.1742-1241.2011.02706.x
 
12. Mann DM, Woodward M, Muntner P, Falzon L, Kronish I. Predictors of nonadherence to statins: a systematic review and meta-analysis. Ann Pharmacother 2010; 44:1410-21.
http://dx.doi.org/10.1345/aph.1P150
 
13. Chan DC, Shrank WH, Cutler D, et al. Patient, physician, and payment predictors of statin adherence. Med Care 2010; 48:196-202.
http://dx.doi.org/10.1097/MLR.0b013e3181c132ad
 
14. Durack-Bown I, Giral P, d'Ivernois JF, et al. Patients' and physicians' perceptions and experience of hypercholesterolaemia: a qualitative study. Br J Gen Pract 2003; 53:851-7.
PMid:14702904 PMCid:PMC1314727
 
15. Goldman RE, Parker DR, Eaton CB, et al. Patients' perceptions of cholesterol, cardiovascular disease risk, and risk communication strategies. Ann Fam Med 2006; 4:205-12.
http://dx.doi.org/10.1370/afm.534
 
16. Fung V, Sinclair F, Wang H, et al. Patients' perspectives on nonadherence to statin therapy: a focus-group study. Perm J 2010; 14:4-10.
PMid:20740125
 
17. McHorney CA. The Adherence Estimator: a brief, proximal screener for patient propensity to adhere to prescription medications for chronic disease. Curr Med Res Opin 2009; 25:215-38.
http://dx.doi.org/10.1185/03007990802619425
 
18. Mann DM, Allegrante JP, Natarajan S, Halm EA, Charlson M. Predictors of adherence to statins for primary prevention. Cardiovasc Drugs Ther 2007; 21:311-6.
http://dx.doi.org/10.1007/s10557-007-6040-4
 
19. McClendon D. Perceived Susceptibility of Cardiovascular Disease as a Moderator of Relationships between Perceived Severity and Cardiovascular Health Promoting Behaviors among Female Registered Nurses (dissertation). Atlanta, GA: Georgia State University, 2011.
 
20. DiMatteo MR, Haskard KB, Williams SL. Health beliefs, disease severity, and patient adherence: a meta-analysis. Med Care 2007; 45:521-8.
http://dx.doi.org/10.1097/MLR.0b013e318032937e
 
21. Yan J, You LM, He JG, et al. Illness perception among Chinese patients with acute myocardial infarction. Patient Educ Couns 2011; 85:398-405.
http://dx.doi.org/10.1016/j.pec.2010.11.010
 
22. Choudhry NK, Setoguchi S, Levin R, Winkelmayer WC, Shrank WH. Trends in adherence to secondary prevention medications in elderly post-myocardial infarction patients. Pharmacoepidemiol Drug Saf 2008; 17:1189-96.
http://dx.doi.org/10.1002/pds.1671
 
23. Shah ND, Dunlay SM, Ting HH, et al. Long-term medication adherence after myocardial infarction: experience of a community. Am J Med 2009; 122:961.e7-13.
 
24. Colivicchi F, Bassi A, Santini M, Caltagirone C. Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke 2007; 38:2652?7.
http://dx.doi.org/10.1161/STROKEAHA.107.487017
 
25. Gialamas A, Aylward P, Vanlint S, Stocks NP. Cholesterol lowering medication - patients' knowledge, attitudes and experiences. Aust Fam Physician 2011; 40:519-22.
PMid:21743861
 
26. Tarn DM, Paterniti DA, Kravitz RL, et al. How much time does it take to prescribe a new medication? Patient Educ Couns 2008; 72:311-9.
http://dx.doi.org/10.1016/j.pec.2008.02.019
 
27. Lytsy P, Westerling R. Patient expectations on lipid-lowering drugs. Patient Educ Couns 2007; 67:143-50.
http://dx.doi.org/10.1016/j.pec.2007.03.004
 
28. McKenney JM, Davidson MH, Jacobson TA, Guyton JR; National Lipid Association Statin Safety Assessment Task Force. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 2006; 97:89C-94C.
http://dx.doi.org/10.1016/j.amjcard.2006.02.030
 
29. Ucar M, Mjörndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 2000; 22:441-57.
http://dx.doi.org/10.2165/00002018-200022060-00003
 
30. Chapman MJ, Carrie A. Mechanisms of statin-induced myopathy: a role for the ubiquitin-proteasome pathway? Arterioscler Thromb Vasc Biol 2005; 25:2441-4.
http://dx.doi.org/10.1161/10.1161/01.ATV.0000194548.11901.a4
 
31. Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. Cardiovasc Drugs Ther 2005; 19:403-14.
http://dx.doi.org/10.1007/s10557-005-5686-z
 
32. Yilmaz MB, Pinar M, Naharci I, et al. Being well-informed about statin is associated with continuous adherence and reaching targets. Cardiovasc Drugs Ther 2005; 19:437-40.
http://dx.doi.org/10.1007/s10557-005-5202-5
 
33. Yilmaz MB, Biyikoglu SF, Guray Y, et al. Level of awareness of on-treatment patients about prescribed statins. Cardiovasc Drugs Ther 2004; 18:399-404.
http://dx.doi.org/10.1007/s10557-005-5065-9
 
34. National Heart, Lung, and Blood Institute. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III); 2001. NIH Publication No. 01-3670.
 
35. Varady KA, Jones PJ. Combination diet and exercise interventions for the treatment of dyslipidemia: an effective preliminary strategy to lower cholesterol levels? J Nutr 2005; 135:1829-35.
PMid:16046704
 
36. Ramsay LE, Yeo WW, Jackson PR. Dietary reduction of serum cholesterol concentration: time to think again. BMJ 1991; 303:953-7.
http://dx.doi.org/10.1136/bmj.303.6808.953
 
37. Jenkins DJ, Kendall CW, Marchie A, et al. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA 2003; 290:502-10.
http://dx.doi.org/10.1001/jama.290.4.502
 
38. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA 2007; 298:61-9.
http://dx.doi.org/10.1001/jama.298.1.61
 
39. Doshi JA, Zhu J, Lee BY, Kimmel SE, Volpp KG. Impact of a prescription copayment increase on lipid-lowering medication adherence in veterans. Circulation 2009; 119:390-7.
http://dx.doi.org/10.1161/CIRCULATIONAHA.108.783944
 
40. Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med 2007; 167:540-50.
http://dx.doi.org/10.1001/archinte.167.6.540
 
41. Choudhry NK, Winkelmayer WC. Medication adherence after myocardial infarction: a long way left to go. J Gen Intern Med 2008; 23:216-8.
http://dx.doi.org/10.1007/s11606-007-0478-8
 
42. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation 2009; 119:3028-35.
http://dx.doi.org/10.1161/CIRCULATIONAHA.108.768986
 
43. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA 2006; 296:2563-71.
http://dx.doi.org/10.1001/jama.296.21.joc60162
 
44. Weinman J, Petrie KJ, Moss-Morris R, Horne R. The illness perception questionnaire: a new method for assessing the cognitive representation of illness. Psychol Health 1996; 11:114-29.
http://dx.doi.org/10.1080/08870449608400270
 
45. Scharloo M, Kaptein AA, Weinman JA, et al. Predicting functional status in patients with rheumatoid arthritis. J Rheumatol 1999; 26:1686-93.
PMid:10451063
 
46. Scharloo M, Kaptein AA, Weinman J, et al. Patients' illness perceptions and coping as predictors of functional status in psoriasis: a 1-year follow-up. Br J Dermatol 2000; 142:899-907.
http://dx.doi.org/10.1046/j.1365-2133.2000.03469.x
 
47. Scharloo M, Kaptein AA, Weinman JA, Willems LN, Rooijmans HG. Physical and psychological correlates of functioning in patients with chronic obstructive pulmonary disease. J Asthma 2000; 37:17-29.
http://dx.doi.org/10.3109/02770900009055425
 
48. Griva K, Myers LB, Newman S. Illness perceptions and self efficacy beliefs in adolescents and young adults with insulin dependent diabetes mellitus. Psychol Health 2000; 15:733-50.
http://dx.doi.org/10.1080/08870440008405578
 
49. Petrie KJ, Weinman J, Sharpe N, Buckley J. Role of patients' view of their illness in predicting return to work and functioning after myocardial infarction: longitudinal study. BMJ 1996; 312:1191-4.
http://dx.doi.org/10.1136/bmj.312.7040.1191
 
50. Zolnierek KB, Dimatteo MR. Physician communication and patient adherence to treatment: a meta-analysis. Med Care 2009; 47:826-34.
http://dx.doi.org/10.1097/MLR.0b013e31819a5acc
 
51. Casebeer L, Huber C, Bennett N, et al. Improving the physician-patient cardiovascular risk dialogue to improve statin adherence. BMC Fam Pract 2009; 10:48.
http://dx.doi.org/10.1186/1471-2296-10-48

Production of a polyclonal antibody against osteogenic protein-1, and its role in the diagnosis of osteoarthritis

Share this Article

Singapore Med J 2014; 55(7): 388-391; http://dx.doi.org/10.11622/smedj.2014092
Production of a polyclonal antibody against osteogenic protein-1, and its role in the diagnosis of osteoarthritis

Bhutia SC, Singh TA, Sherpa ML
Correspondence: Dr Mingma Lhamu Sherpa, mingmals@yahoo.com

ABSTRACT
INTRODUCTION Osteoarthritis (OA) is a progressive degenerative disorder of the articular cartilage. Available diagnostic radiography has been poorly associated with the progress and severity of this clinical disease. As osteogenic protein-1 (OP-1) has been identified as a bone morphogenetic protein with a major role in cartilage repair, we aimed to evaluate its potential role in the diagnosis of OA.
METHODS This was an experimental study conducted at the Department of Biochemistry, Sikkim Manipal Institute of Medical Sciences, India. Polyclonal antibodies (i.e. anti-OP-1[f]) were raised against OP-1 in mice, and subsequently used in a sandwich enzyme-linked immunosorbent assay (ELISA) to detect the presence of OP-1 in the synovial fluids of 75 osteoarthritic patients. For the purpose of correlation, the radiographic assessments of the knees of the 75 patients were graded using the Kellgren-Lawrence scoring system.
RESULT The polyclonal antibody (i.e. anti-OP-1[f]) raised against OP-1 was able to detect the presence of OP-1 in the synovial fluids of all the osteoarthritic patients via sandwich ELISA. The level of the OP-1 was found to be much higher than the reference range and correlated positively with the severity of OA (r = 0.24; p = 0.04).
CONCLUSION Our study shows that the polyclonal antibody, anti OP-1(f), could be used for the immunodiagnosis of osteoarthritis via sandwich ELISA.

Keywords: osteoarthritis, osteogenic protein-1, sandwich ELISA, synovial fluid
Singapore Med J 2014; 55(7): 388-391; http://dx.doi.org/10.11622/smedj.2014092

REFERENCES

1. Hayashi M, Muneta T, Ju YJ, Mochizuki T, Sekiya I. Weekly intra-articular injections of bone morphogenetic protein-7 inhibits osteoarthritis progression. Arthritis Res Ther 2008; 10:R118.
http://dx.doi.org/10.1186/ar2521
 
2. Chambers MG, Bayliss MT, Mason RM. Chondrocyte cytokine and growth factor expression in murine osteoarthritis. Osteoarthritis Cartilage 1997; 5:301-8.
http://dx.doi.org/10.1016/S1063-4584(97)80034-9
 
3. Sharma MK, Swami HM, Bhatia V, et al. An epidemiological study of correlates of osteoarthritis in geriatric population of UT Chandigarh. IndianJ Community Med 2007; 32:77-8.
http://dx.doi.org/10.4103/0970-0218.53414
 
4. Lawrence JS, Bremner JM, Bier F. Osteo-arthrosis. Prevalence in the population and relationship between symptoms and x-ray changes. Ann Rheum Dis 1966; 25:1-24.
PMid:5905334 PMCid:PMC2453365
 
5. Loeser RF. Age-related changes in the musculoskeletal system and the development of osteoarthritis. Clin Geriatr Med 2010; 26:371-86.
http://dx.doi.org/10.1016/j.cger.2010.03.002
 
6. Moskowitz R, Goldberg V, Vowell DS, Altman RD, Buckwalter J. Noninvasive markers in osteoarthritis. Osteoarthritis: Diagnosis and Medical/Surgical Management. 3rd ed. Philadelphia: Saunders, 2001: 293-313.
 
7. Chubinskaya S, Hurtig M, Rueger DC. OP-1/BMP-7 in cartilage repair. Int Orthop 2007; 31:773-81.
http://dx.doi.org/10.1007/s00264-007-0423-9
 
8. Desmyter S, Goubau Y, Benahmed N, de Wever A, Verdonk R. The role of bone morphogenetic protein-7 (Osteogenic Protein-1) in the treatment of tibial fracture non-unions. An overview of the use in Belgium. Acta Orthop Belg 2008; 74:534-7.
PMid:18811040
 
9. Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986; 29:1039-49.
http://dx.doi.org/10.1002/art.1780290816
 
10. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 1957; 16:494-502.
http://dx.doi.org/10.1136/ard.16.4.494
 
11. Avrameas S. Coupling of enzymes to proteins with glutaraldehyde. Use of the conjugates for the detection of antigens and antibodies. Immunochemistry 1969; 6:43-52.
http://dx.doi.org/10.1016/0019-2791(69)90177-3
 
12. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 1979; 76:4350-4.
http://dx.doi.org/10.1073/pnas.76.9.4350
 
13. Shapiro AL, Vi-uela E, Maizel JV Jr. Molecular weight estimation of polypeptide chains by electrophoresis in SDS-polyacrylamide gels. Biochem Biophys Res Commun 1967; 28:815-20.
http://dx.doi.org/10.1016/0006-291X(67)90391-9
 
14. Guellaen G, Goodhardtt M, Hanoune J. Preparative SDS gel electrophoresis. In: J Craigventer, L Harrison, eds. Receptor purification procedures. New York: Alan R Liss, 1984; 2:109-24.
 
15. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193:265-75.
PMid:14907713
 
16. Committee for the Purpose of Control and Supervision on Experiments on Animals. CPCSEA Guidelines For Laboratory Animal Facility [online]. Available at: http://icmr.nic.in/bioethics/final_cpcsea.pdf. Accessed November 12, 2012.
 
17. Cheirmaraj K, Reddy MV, Harinath BC. Diagnostic use of polyclonal antibodies raised in mouse ascitic fluid in bancroftian filariasis. J Immunoassay 1990; 11:429-44.
http://dx.doi.org/10.1080/01971529008055043
 
18. Reddy MV, Prasad GB, Harinath BC. Isolation and evaluation of antigens from microfilaraemia plasma and immune complexes for diagnosis of bancroftian filariasis. Indian J Pathol Microbiol 1986; 29:179-88.
PMid:3546110
 
19. Collins DH. The Pathology of Articular and Spinal Diseases. Edward Arnold: London Osteoarthritis, 1949: 74-115.
 
20. Chubinskaya S, Kumar B, Merrihew C, et al. Age-related changes in cartilage endogenous osteogenic protein-1 (OP-1). Biochim Biophys Acta 2002; 1588:126-34.
http://dx.doi.org/10.1016/S0925-4439(02)00158-8
 
21. Merrihew C, Kumar B, Heretis K, et al. Alterations in endogenous osteogenic protein-1 with degeneration of human articular cartilage. J Orthop Res 2003; 21:899-907.
http://dx.doi.org/10.1016/S0736-0266(03)00055-X
 
22. Chubinskaya S, Merrihew C, Cs-Szabo G, et al. Human articular chondrocytes express osteogenic protein-1. J Histochem Cytochem 2000; 48:239-50.
http://dx.doi.org/10.1177/002215540004800209
 
23. Honsawek S, Chayanupatkul M, Tanavalee A, et al. Relationship of plasma and synovial fluid BMP-7 with disease severity in knee osteoarthritis patients: a pilot study. Int Orthop 2009; 33:1171-5.
http://dx.doi.org/10.1007/s00264-009-0751-z
 
24. Rueger DC, Chubinskaya S. BMPs in articular cartilage repair. In: Vukicevic S, Sampath KT, eds. Bone morphogenetic proteins: regeneration of bone and beyond. Birkhauser: Basel, 2004: 109-32.
http://dx.doi.org/10.1007/978-3-0348-7857-9_5
 
25. Chubinskaya S, Frank BS, Michalska M, et al. Osteogenic protein 1 in synovial fluid from patients with rheumatoid arthritis or osteoarthritis: relationship with disease and levels of hyaluronan and antigenic keratan sulfate. Arthritis Res Ther 2006, 8:R73.
http://dx.doi.org/10.1186/ar1947